Sign Up | Log In | What is SocialPicks?

6 pts

Opinion on Cubist Pharmaceuticals Inc. (CBST) Sector: Healthcare > Industry: Biotechnology & Drugs
EU approves Cubicin

Nov 14, 2008 05:54 PM GMT

ariesdragon

Return	Risk
+8.03%	LOW

Analyst

Profile & Performance

Subscribe to author

EU approves Novartis' Cubicin to treat hospital infections

FDLI SmartBrief | 11/07/2008

The European Union has approved Cubicin for expanded use in patients suffering from potentially fatal infections commonly contracted during hospital stays. The two new indications approved were right-sided infective endocarditis due to Staphylococcus aureus, an infection of the heart valve, and Staphylococcus aureus bacteremia, a bloodstream infection. Reuters (09/05)

CBST: This call was made on 11/14/08 @ $24.8

Rating:	$24.8 (11/14/08)
Gain/Loss:	-30.81% in 231 days

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+42.40%	270
2	Gerald Greene	18.14	+59.31%	138
3	stockmarketfunding.com	17.66	+22.00%	34
4	akiralegrand	13.47	+15.91%	48
5	anup2104	12.13	+37.83%	11

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
LEH	Lehman Brothers Holdings Inc
FSLR	First Solar Inc.
JNJ	Johnson & Johnson
WFC	Wells Fargo & Company
ETFC	E*Trade Financial Corp
POT	Potash Corp. of Saskatchewan Inc.

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

ARYX		Extreme FDA Calendar Trades: 18 Stocks Under $5 by Mike Havrilla
DGX		Quest Diagnostics Inc. by Marian Filo
LNC		Accepting TARP is a VERY bad sign by utopius
KG		FDA Calendar Updates: ACUR, KG, MYRX, NEPH, Eisai by Mike Havrilla
ACOR		FDA Calendar Updates: ACOR, HGSI, RPRX, Pharming by Mike Havrilla

... more »

Cubist Pharmaceuticals Inc. (CBST)

SocialPicks Sentiment:

This Quarter's Sentiment:

All:

100.0%

Top:

100.0%

Get Daily Email Alerts

Subscribe to ariesdragon

Receive Free Ideas Daily for This Sector

Latest Picks by ariesdragon

Symbol	SP Sentiment	Return	Since
AGU		+16.27%	01/29/09
MUR		+12.24%	01/29/09
OXY		+9.16%	01/29/09
NJR	N/A	-9.43%	01/29/09
DTV		+13.97%	11/24/08

View All >

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Opinion on Cubist Pharmaceuticals Inc. (CBST) Sector: Healthcare > Industry: Biotechnology & Drugs EU approves Cubicin

EU approves Novartis' Cubicin to treat hospital infections

Opinion on Cubist Pharmaceuticals Inc. (CBST) Sector: Healthcare > Industry: Biotechnology & Drugs
EU approves Cubicin